SEC Form 4 · accession 0001104659-16-153350
Ra Pharmaceuticals, Inc. · RARX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Charles Lubner
Officer — EVP & CFO
Period of report
Oct 31, 2016
Accepted (ET)
Oct 31, 2016 · 4:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001481512
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF1 | $2.87 | Oct 31, 2016 | A | 29,285 | A | — | Mar 1, 2026 | Common Stock | 29,285 | 29,285 | D |
Explanation of responses
- F1These stock options vest in 48 equal monthly installments at the end of each month following October 31, 2016, which was the date of the consummation of the initial public offering of the Issuer.
Remarks
Exhibit 24.1: Limited Power of Attorney